Peterson L C, Bloomfield C D, Brunning R D
Br J Haematol. 1980 Apr;44(4):563-7. doi: 10.1111/j.1365-2141.1980.tb08710.x.
The value of the Rai clinical staging system and lymphocyte morphology in predicting survival in chronic lymphocytic leukaemia was examined in 83 patients who had been followed for at least 5 years. Patients with less clinical evidence of disease (Stages 0 and I) had significantly longer survivals than patients with more evidence of disease (Stages II, III and IV). Patients in whom greater than 35% of the lymphocytes resembled benign atypical lymphocytes had longer survivals than those in whom most of the lymphocytes had narrow rims of cytoplasm and coarsely clumped chromatin. The survival differences in the morphologic groups were less striking than those in the clinical stages, and when the morphological groups were corrected for clinical stage, no significant differences in survival among the morphologic groups remained.
对83例随访至少5年的慢性淋巴细胞白血病患者，研究了Rai临床分期系统和淋巴细胞形态在预测生存方面的价值。疾病临床证据较少的患者（0期和I期）比疾病证据较多的患者（II期、III期和IV期）生存期显著更长。淋巴细胞中超过35%类似良性非典型淋巴细胞的患者比大多数淋巴细胞胞质边缘狭窄且染色质粗块状聚集的患者生存期更长。形态学分组中的生存差异不如临床分期中的显著，并且当对形态学分组进行临床分期校正后，形态学分组之间的生存无显著差异。
